Options traders are aggressively buying calls on PNC even as short sellers quietly build positions. The divergence is sharp and has been consistent across the past week.
The put-call ratio on PNC hit 0.85 on August 20. That is 3.6 standard deviations below the 20-day mean of 0.91. For context, the 52-week low PCR sits at 0.71 — so this reading is near historically bullish territory. This is the third consecutive session where the PCR has printed more than 3.5 standard deviations below the mean. That kind of persistence in options positioning is unusual for a large-cap regional bank.
Calls are clearly dominating the options tape. This is not a one-day anomaly.
Short interest has risen roughly 10–15% over the past week to 1.87% of free float. That is still a low absolute level. This is not a heavily shorted stock. But the direction matters — shorts have been adding steadily since early August.
The cost to borrow rose 59% week-over-week to 0.49%. That sounds dramatic. In practice, 0.49% remains extremely cheap to borrow. The lending market for PNC is wide open. Availability sits at the maximum reading in the dataset — more than 331 million shares remain available to borrow. There is no squeeze risk here.
The short build looks measured, not aggressive. It is the kind of incremental positioning that often reflects hedging against a stock that has had a strong run, rather than a concentrated directional bet.
A cluster of price target increases followed PNC's July earnings. JP Morgan raised its target to $269.50. Citigroup moved to $290. Wells Fargo's Mike Mayo lifted to $285. The mean target across the analyst group sits at $277.73 — a gap of roughly 15% above the current price of $241.62.
PNC is down 5.3% over the past week. That pullback has widened the discount to analyst targets further. Most firms maintained Overweight or Outperform ratings without flinching.
The weakness is not PNC-specific. Peers are all lower on the week. FITB fell 5.9%. MTB dropped 5.9%. CFG was down 5.9%. The entire regional banking complex has sold off in unison. PNC's 5.3% weekly decline tracks almost exactly with the peer group.
Next earnings are scheduled for October 15.
What to watch: Whether the PCR reverts toward its 20-day mean as the stock stabilizes — or whether call buyers continue pressing despite the sector-wide weakness.
See the live data behind this article on ORTEX.
Open PNC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
